HRYZ-T101

N/A

Report date: 2024/11/28 11:09:28

Base Information

Drug NameHRYZ-T101
Drug Alias NameHRYZ-T101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsSolid tumoursPenile NeoplasmsVulvar Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHengrui Yuanzheng (Shanghai) Biotechnology Co LtdHRYZ Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHRYZ Biotech Co LtdHengrui Yuanzheng (Shanghai) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPenile NeoplasmsVulvar Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A